UCB Provides Update on U.S. Regulatory Review of Bimekizumab

Brussels (Belgium), 19 September 2023 – UCB, a global biopharmaceutical company, today provided an update on the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis. UCB has…Original Article